BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

We Claim:

1 Pyrrolo[2,1-*c*][1,4]benzodiazepine hybrid of the formula given below wherein R is H or OH and n is 2-3



n = 2-3
R = H, OH

R' =  or 

2 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



3 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



4 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



5 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



6 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



5 7 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



8 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



9 Pyrrolobenzodiazepine hybrid as claimed in claim 1 of the structure



10

10 A process for the preparation of a compound of the formula wherein R is H or OH and n is 2-3



n = 2-3
R = H, OH

R' =  or 

the process comprising reacting reacting an acridone or an acridine acid with (2*S*)-N-[4-(n'-aminoalkyloxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I



Formula I

in the presence of EDCI and HOBt in organic solvent for a period of 24 h to obtain (2*S*)-N-{4-[n'-(4"-acrido-nylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl} pyrrolidine-2-carboxaldehyde diethyl thioacetal II / (2*S*)-N-{4-[n'-(4"-acridinylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula V where 'n' is 2-3,



Formula II



Formula V

isolating the compound of formula II/formula V and then reducing the compounds of formula II/formula V with $SnCl_2.2H_2O$ in presence of an organic solvent up to a reflux temperature, isolating the (2*S*)-N-{4-[n'-(4"-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrroli-dine-2-carboxaldehydediethylthioacetal of formula III/(2*S*)-N-{4-[n'-(4"-acridinylcarbox-amido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula VI where n is 2-3,



Formula III



Formula VI

reacting compound of formula III/formula VI with a deprotecting agent to obtain the desired pyrrolo[2,1-*c*][1,4]benzodiazepine hybrid.

11 A process as claimed in claim 10 wherein the organic solvent used for the reaction of the acridone/acridine acid with compound of formula I comprises dimethyl furan.

12 A process as claimed in claim 10 wherein the compound of formula II/formula V is isolated by washing with saturated $NaHCO_3$, brine, drying and evaporation of the solvent.

13 A process as claimed in claim 10 wherein the organic solvent used during the reduction of compound of formula II/formula V comprises methanol.

14 A process as claimed in claim 10 wherein the compound of formula III/formula V is isolated by adjusting the pH of the reaction mixture to about pH 8 with a saturated

$NaHCO_3$ solution, diluting with ethyl acetate, filtering through celite and extracted an organic phase and drying the organic phase over Na_2SO_4.

15 A process as claimed in claim 10 wherein the deprotecting agent used for obtaining the compound of formula IV/formula VII comprises $HgCl_2$ and $CaCO_3$ in MeCN-water (4:1).

16 A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula given below wherein R is H or OH and n is 2-3 and a pharmaceutically acceptable additive.



n = 2-3
R = H, OH

R' =  or

17 A method for the treatment of cancer in a subject suffering from the same comprising administering a pharmaceutically effective amount of a compound of the formula



n = 2-3
R = H, OH

R' =  or

wherein R is H or OH and n is 2-3.

18. A method as claimed in claim 17 wherein the patient is a mammal.

19. A method as claimed in claim 17 wherein the mammal is a human being.

20. A method as claimed in claim 17 wherein the cancer is selected from the group consisting of leukemia, non-small cell, lung, colon, CNS, melanoma, ovarian, renal, prostate and breast.

21. Use of a compound of formula given below for the treatment of cancer selected from the group consisting of leukemia, non-small cell, lung, colon, CNS, melanoma, ovarian, renal, prostate and breast in a subject suffering from the same.



n = 2-3
R = H, OH

R' =